SpeeDx and MolGen Announce Partnership for COVID-19 Test Solution
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the two company’s technology.
“Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.” said Colin Denver, SpeeDx CEO.
Read the full press release